Anlon Healthcare IPO: Key Highlights, Financials & GMP 

By Finchetak.com August 25, 2025 — IPO Basics

• Listing Dates: Opens on August 26, 2025, closes on August 29, 2025, with listing expected on September 3, 2025.
  
  

• Price Band: ₹86–₹91 per share.
  
  

• Issue Size: Fresh issue of 1.33 crore shares, aiming to raise approximately ₹121 crore.
  
  

• Allocation: About 75% for institutional investors, 15% for non-institutional, and 10% for retail. Minimum retail investment is around ₹15,000.
  
  

Use of Funds

• Expansion of manufacturing facilities.
  
  

• Repayment of some existing debt.
  
  

• Working capital needs.
  
  

• General corporate expenses.
  
  

Financial Performance (Past 2–3 Years)

• FY 23 to FY 24: Revenue dropped from ₹112.9 crore to around ₹66.6 crore, but profit after tax rose from ₹5.8 crore to ₹9.7 crore.
  
  

• FY 25 (10-month period): Revenue climbed to about ₹77.4 crore; net profit reached nearly ₹12 crore.
  
  

• Full FY 25 Outlook: Revenue estimated around ₹120 crore, with profit after tax approximately ₹20.5 crore. Efficiency metrics show strong returns: ROE around 40%, ROCE near 22%, and a debt-to-equity ratio of about 0.73.
  
  

Grey Market Premium (GMP) – What Does It Say?

• Currently (as of latest updates): No GMP activity has been observed—meaning there's no unofficial pricing in the grey market yet.
  
  

• But some trackers suggest: A potential GMP of ₹5 above the issue price, implying a possible listing near ₹96 (roughly 5.5% higher than the upper price band).
  
  

• Other estimates show: A GMP of ₹20–₹25, suggesting a 20–25% premium in listing gains.
  
  

Strengths & Why Investors Are Watching

• High Growth in Profit: Strong jump in net profit despite dipping revenue earlier, and healthy rebound afterward.
  
  

• Global Certifications & Export Reach: Holds regulatory approvals and exports products to multiple international markets.
  
  

• Product Pipeline: Robust product portfolio with several items under development or commercial use.
  
  

• Improving Operational Metrics: Stellar return ratios and moderate leverage indicate efficient use of capital.
  
  

Key Risks to Consider

• Little Retail Allocation (10%)—limited access for small investors.
  
  

• High Working Capital Needs—a significant portion of IPO proceeds going into operations.
  
  

• Regulatory & Market Volatility—pharma ingredient industry is sensitive to policy changes and demand cycles.
  
  

• Uncertain GMP Signals—some variation in unofficial pricing estimates can cause mixed investor expectations.

Takeaway

Anlon Healthcare’s IPO showcases strong profitability, efficient operations, and a clear growth path in the pharmaceutical ingredients space. While some GMP estimates imply attractive listing prospects, others remain conservative. The limited retail allocation, regulatory exposure, and high capital requirement mean that cautious investors should review the company’s fundamentals and IPO terms carefully.